MA-WASABI/ZERO-CIRCLE
10.7.2024 15:01:34 CEST | Business Wire | Press release
Zero Circle, a sustainable finance marketplace, and Wasabi Technologies, the hot cloud storage company, have partnered to develop a suite of sustainability-focused solutions for cloud storage that give businesses the data they need to make decisions that reduce their environmental impact.
Wasabi cloud storage integrated Zero Circle’s invoice-based carbon footprint calculator to give customers transparency and real-time assessment of their carbon footprint. Customers can upload their Wasabi invoice to Zero Circle’s carbon calculator to determine their estimated CO2 footprint based on actual data stored in a Wasabi storage region, increasing the accuracy of their ESG benchmarking with their peers and helping them make more sustainable business decisions.
According to the Wasabi 2024 Global Cloud Storage Index, sustainability ranks among the top three most important considerations for buyers when choosing a cloud storage service. Factors like ESG commitments, energy-efficient architecture design, and native tools for carbon footprint calculation are all increasingly important to modern enterprises as they adopt cloud infrastructure services. As a result, the survey found that cloud service providers must deliver accurate, reliable tools, metrics, and programs to meet customer expectations.
This joint initiative leverages Zero Circle's deep expertise in sustainability and product carbon footprint measurement with Wasabi's leadership in cloud storage to drive sustainability in the cloud storage industry and create innovative solutions that support businesses with their sustainability initiatives. The solution's unique features and flexibility make it a powerful resource for companies seeking to measure and track their cloud sustainability, such as real-time emissions calculations integrated directly into the purchases from supply chain partners.
“Partnering with Zero Circle underscores Wasabi’s dedication to providing top-tier, sustainable cloud storage solutions,” said David Boland, vice president of cloud strategy at Wasabi Technologies. “Zero Circle's carbon footprint calculation has already enabled Wasabi, our partners, and customers to gain a deeper understanding of our environmental impact. By integrating this solution into our supply chain, we are amplifying these benefits for everyone involved.”
"Announcing our collaboration with Wasabi marks a significant step in advancing environmental sustainability within the cloud storage sector,” said Hemanth Setty, founder and CEO of Zero Circle. “This partnership leverages our combined strengths and underscores our mutual dedication to fostering a more sustainable future, paving the way for innovative and groundbreaking solutions.”
The carbon footprint solution is now available to all Wasabi customers. The Zero Circle – Wasabi collaboration will also explore other eco-friendly initiatives, such as renewable energy procurement and carbon offset programs in an effort to further reduce environmental impact of cloud storage.
Additional Resources:
- For more information on Wasabi’s work with Zero Circle, visit wasabi.com/sustainability.
- To try Zero Circle’s invoiced-based carbon footprint calculator for Wasabi, visit https://cust.zerocircle.eco/wasabi.
- Join Wasabi, Zero Circle, and 451 Research July 16 at 1 p.m. ET/10 a.m. PT to learn how establishing sustainability goals for IT can help your business meet regulatory compliance more quickly. Read more details here.
About Zero Circle
Zero Circle is a green finance marketplace that simplifies access to green capital for mid-tier businesses. Its AI-powered platform streamlines sustainability assessments and reporting and automates financial and sustainability KPIs to incentivize green financing. The company helps its customers finance and build sustainable practices by tracking, managing, and reporting sustainability and financial performance with lenders, partners, and customers.
Click here to learn more about Zero Circle or follow them on LinkedIn and Twitter.
About Wasabi Technologies
Recognized as one of the technology industry’s fastest growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710254246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom